Abstract

Consumption of omega-3 fatty acids, including the precursor α-linolenic acid (ALA) is often sub-optimal and not in line with international guidelines. Supplementation is debatable, but some individuals, e.g., pre-diabetic, low-grade inflammation, cardiometabolic yet otherwise healthy subjects, might benefit from supra-physiological omega-3 intake, particularly to lessen inflammation. We explored the feasibility of a large clinical trial by performing a pilot study to evaluate adherence, palatability, and self-reported side effects of ALA administration in a group of volunteers. We enrolled 12 individuals with borderline dyslipidemia or overweight, treated with dietary advice according to international guidelines and who had insufficient intakes of essential fatty acids. Subjects were followed for nutritional counselling and were matched with appropriate controls. Patients were administered 6 g/day of ALA, for two months. We report the absence of side effects. such as fishy aftertaste and gastrointestinal distress, in addition to a slight decrease of C-reactive protein concentrations (Identifier: ISRCTN13118704).

摘要

omega-3 脂肪酸的摄入量，包括前体 α-亚麻酸 (ALA)，通常是次优的，不符合国际准则。补充剂是有争议的，但一些个体，例如糖尿病前期、低度炎症、心脏代谢但健康的受试者，可能会受益于超生理的 omega-3 摄入量，特别是减轻炎症。我们通过进行一项试点研究来评估一组志愿者中 ALA 给药的依从性、适口性和自我报告的副作用，从而探索了一项大型临床试验的可行性。我们招募了 12 名患有临界血脂异常或超重的人，他们根据国际指南接受了饮食建议，并且必需脂肪酸摄入量不足。受试者接受营养咨询，并与适当的对照相匹配。患者服用 6 克/天的 ALA，持续两个月。我们报告没有副作用。如鱼腥味和胃肠道不适，以及 C 反应蛋白浓度略有下降（标识符：ISRCTN13118704）。